Living With Climate Change: Cities generate dangerous underground heat. It could be an energy source instead.
Underground climate change poses a ‘silent hazard’ for slowly sinking buildings in Chicago and other cities, researchers at Northwestern University find.
Market Extra: Here’s how Wednesday’s inflation report could push U.S. stocks even higher
Expectations for the Federal Reserve to push interest rates even higher this year have helped to put a lid on U.S. stocks' rebound rally in...
: Bank of America will pay customers $100 million for ‘double-dipping’ on fees and opening fake accounts. Will you be one of them?
The $250 million sum includes $100 million in redress to affected customers, regulators said.
: Mastercard’s stock flirts with first new record high in 17 months
Shares of Mastercard Inc. MA were ahead 1.25% in Tuesday trading, changing hands at $397.05. That puts the stock on pace to surpass the record...
: Coinbase’s stock flies toward an 11-month high, and has soared more than 25% this month
Shares of Coinbase Global Inc. COIN spiked 10.3% higher in afternoon trading Tuesday, to put them on track to close at an 11-month high, despite...
: Dow scores best day in a month, stocks post back-to-back gains as investors await inflation update
Stocks scored back-to-back gains on Tuesday as investors waited on an inflation update due Wednesday from the June consumer-price index. The Dow Jones Industrial Average...
EU expands Wegovy, Ozempic probe over suicide risks to include other weight loss, diabetes drugs
The European Medicines Agency didn't specify which additional GLP-1 drugs are now being investigated, but it could potentially include Eli Lilly's Mounjaro.
The Ratings Game: Netflix has been getting a lot of love lately. Could that spell trouble ahead of earnings?
Netflix has been feeling the love lately on Wall Street, and now one analyst wonders if expectations have gotten ahead of themselves.
: EU regulator is reviewing weight-loss drugs Ozempic and Wegovy for risk of suicidal thoughts and self-harm
The European Medicines Agency is reviewing data on the popular new class of drugs used for weight loss and Type 2 diabetes.